Loss-of-function mutation in inositol monophosphatase 1 (IMPA1) results in abnormal synchrony in resting-state EEG

Christopher P. Walker†Email author View ORCID ID profile,
Andre L. S. Pessoa†,
Thalita Figueiredo†,
Megan Rafferty,
Uirá S. Melo,
Paulo R. Nóbrega,
Nicholas Murphy,
Fernando Kok,
Mayana Zatz,
Silvana Santos and
Raymond Y. Cho

†Contributed equally

Orphanet Journal of Rare Diseases201914:3

https://doi.org/10.1186/s13023-018-0977-1

Received: 14 August 2018
Accepted: 11 December 2018
Published: 7 January 2019

Abstract

Background

Dysregulation of the inositol cycle is implicated in a wide variety of human diseases, including developmental defects and neurological diseases. A homozygous frameshift mutation in IMPA1, coding for the enzyme inositol monophosphatase 1 (IMPase), has recently been associated with severe intellectual disability (ID) in a geographically isolated consanguineous family in Northeastern Brazil (Figueredo et al., 2016). However, the neurophysiologic mechanisms that mediate the IMPA1 mutation and associated ID phenotype have not been characterized. To this end, resting EEG (eyes-open and eyes-closed) was collected from the Figueredo et al. pedigree. Quantitative EEG measures, including mean power, dominant frequency and dominant frequency variability, were investigated for allelic associations using multivariate family-based association test using generalized estimating equations.

Results

We found that the IMPA1 mutation was associated with relative decreases in frontal theta band power as well as altered alpha-band variability with no regional specificity during the eyes-open condition. For the eyes-closed condition, there was altered dominant theta frequency variability in the central and parietal regions.

Conclusions

These findings represent the first human in vivo phenotypic assessment of brain function disturbances associated with a loss-of-function IMPA1 mutation, and thus an important first step towards an understanding the pathophysiologic mechanisms of intellectual disability associated with the mutation that affects this critical metabolic pathway.